Plaque Psoriasis — Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
Citation(s)
A Randomized, Double-blind, Multi-center, Parallel Control Phase 3 Study to Compare the Efficacy and Safety of Full Human Anti-TNF Alpha Antibody (HLX03) Versus Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis